Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
T1

From: Cystic presentation of primary hepatic neuroendocrine tumour: a case report with a brief review of literature

Table 1. Comparison of cases of PHNETs with predominant cystic change

Various parameters	Kim et al. [1]	Present case
Age (years)	51	73
Gender	Female	Male
Clinical presentation	Abdominal discomfort Mild dyspnoea	Abdominal pain Bilious vomiting Significant weight loss
Radiological findings	Left lobe of the liver: cystic; non-smooth; multiseptated mass lesion; occupying hepatic segments II and III; D/D-mucinous cystadenoma	Right lobe of the liver: well-circumscribed hypoattenuating cystic lesion; D/D-biliary cystadenoma; hydatid cyst
Gross	Exophytic tumour 14 cm in greatest dimension Cut surface: solid with varying multiple cysts	Cystic tumour 18.5 cm in greatest dimension Cut surface: predominantly cystic; uniloculated
Microscopy	Tumour cells in a trabecular or cribriform pattern	Tumour cells in an acinar, glandular, and focal papillary pattern
Lymphovascular and satellite nodules	Absent	Present
IHC: Cg; synaptophysin	Both were positive	Both were positive (Ki-67: 10–12%)

Return to article view

D/D: differential diagnosis

Declarations

Author contributions

ML and S Garg: Conceptualization, Formal analysis, Writing—original draft. S Gurwale and CG: Validation, Supervision, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study (case report) has been waived by Ethics Committee of Dr. D. Y. Patil Vidyapeeth. Since this is a report involving unusual finding and will increase awareness of such observation among faculty and students and the waiver will not adversely affect the rights and welfare of the concerned patient. Hence, waiver is granted for this case report, and complies with the Declaration of Helsinki. The Ref. No. is I.E.S.C./85/2022.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Kim JM, Lee WA, Shin HD, Song IH, Kim SB. Cystic primary hepatic neuroendocrine tumor. Korean J Gastroenterol. 2021;78:300–4. [DOI] [PubMed]

Hu HX, Yu T. Primary hepatic neuroendocrine tumors: a case report. Medicine (Baltimore). 2019;98:e18278. [DOI] [PubMed] [PMC]

Wang LX, Liu K, Lin GW, Jiang T. Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathology. Cancer Imaging. 2015;15:13. [DOI] [PubMed] [PMC]

Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol. 2018;18:3. [DOI] [PubMed] [PMC]

Song JE, Kim BS, Lee CH. Primary hepatic neuroendocrine tumor: a case report and literature review. World J Clin Cases. 2016;4:243–7. [DOI] [PubMed] [PMC]

Hwang S, Lee YJ, Lee SG, Kim CW, Kim KH, Ahn CS, et al. Surgical treatment of primary neuroendocrine tumors of the liver. J Gastrointest Surg. 2008;12:725–30. [DOI] [PubMed]

Shetty PK, Baliga SV, Balaiah K, Gnana PS. Primary hepatic neuroendocrine tumor: an unusual cystic presentation. Indian J Pathol Microbiol. 2010;53:760–2. [DOI] [PubMed]

Wängberg B, Nilsson O, Johanson V, Kölby L, Forssell-Aronsson E, Andersson P, et al. Somatostatin receptors in the diagnosis and therapy of neuroendocrine tumors. Oncologist. 1997;2:50–8. [DOI] [PubMed]

Gorden P, Comi R, Maton P, Go VLW. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Int Med. 1989;110:35–50. [DOI] [PubMed]

10.

Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121:1172–86. [DOI] [PubMed]